Submit Search
Upload
17. citicoline in ischemic stroke in mexico
âą
1 like
âą
1,341 views
Erwin Chiquete, MD, PhD
Follow
Citicoline in Mexico
Read less
Read more
Health & Medicine
Business
Report
Share
Report
Share
1 of 6
Download now
Download to read offline
Recommended
Diuretics in CKD
Diuretics in CKD
Vishal Golay
Â
Management of seizures
Management of seizures
Praveen Nagula
Â
Management of stroke
Management of stroke
Chindo Mallum
Â
acute heart failure:therapeutic update
acute heart failure:therapeutic update
magdy elmasry
Â
Nephrotoxic drugs
Nephrotoxic drugs
Pravin Prasad
Â
Pharmacological management of heart failure
Pharmacological management of heart failure
Naser Tadvi
Â
Antiplatelet drugs (antithrombotics)
Antiplatelet drugs (antithrombotics)
http://neigrihms.gov.in/
Â
Drug induced nephrotoxicity
Drug induced nephrotoxicity
saqibzaman11
Â
Recommended
Diuretics in CKD
Diuretics in CKD
Vishal Golay
Â
Management of seizures
Management of seizures
Praveen Nagula
Â
Management of stroke
Management of stroke
Chindo Mallum
Â
acute heart failure:therapeutic update
acute heart failure:therapeutic update
magdy elmasry
Â
Nephrotoxic drugs
Nephrotoxic drugs
Pravin Prasad
Â
Pharmacological management of heart failure
Pharmacological management of heart failure
Naser Tadvi
Â
Antiplatelet drugs (antithrombotics)
Antiplatelet drugs (antithrombotics)
http://neigrihms.gov.in/
Â
Drug induced nephrotoxicity
Drug induced nephrotoxicity
saqibzaman11
Â
Antiplatelet and fibrinolytics
Antiplatelet and fibrinolytics
Kaushik Mukhopadhyay
Â
Ranolazine
Ranolazine
Dr Siva subramaniyan
Â
Uremic Encephalopathy- A Neurologist's Point of View
Uremic Encephalopathy- A Neurologist's Point of View
sm171181
Â
Angiotensin receptor blockers
Angiotensin receptor blockers
Mahatma Gandhi Medical College & Hospital
Â
Renal replacement therapy
Renal replacement therapy
Manoj Prabhakar
Â
Hyponatremia ppt .final
Hyponatremia ppt .final
Arun Karmakar
Â
Statin
Statin
Sanjoy Kumar Saha
Â
Antiarrhythmic drugs
Antiarrhythmic drugs
Naser Tadvi
Â
Semaglutide journal club
Semaglutide journal club
Bhargav Kiran
Â
Hypertension 2020 Updated Guidelines
Hypertension 2020 Updated Guidelines
Dr. Aryan (Anish Dhakal)
Â
Antianginal drugs and drugs used in ischaemia - drdhriti
Antianginal drugs and drugs used in ischaemia - drdhriti
http://neigrihms.gov.in/
Â
Stroke
Stroke
Rashna Sharmin
Â
hypernatremia
hypernatremia
Mehakinder Singh
Â
Pharmacological management of migraine
Pharmacological management of migraine
uma advani
Â
Ticagrelor
Ticagrelor
Himanshu Rana
Â
Diabetic dyslipidemia and Saroglitazar
Diabetic dyslipidemia and Saroglitazar
Dr Vivek Baliga
Â
Benzodiazepines toxicity
Benzodiazepines toxicity
Amira Badr
Â
Antipsychotics
Antipsychotics
Naser Tadvi
Â
Hyperkalemia 160108171542
Hyperkalemia 160108171542
Indhu Reddy
Â
Acute kidney injury
Acute kidney injury
aravind ps
Â
Neurotransmitters and its mechanism of action
Neurotransmitters and its mechanism of action
Parthasarathy Ravichandran
Â
Mechanism of drug action
Mechanism of drug action
Deepthi P Ramachandran
Â
More Related Content
What's hot
Antiplatelet and fibrinolytics
Antiplatelet and fibrinolytics
Kaushik Mukhopadhyay
Â
Ranolazine
Ranolazine
Dr Siva subramaniyan
Â
Uremic Encephalopathy- A Neurologist's Point of View
Uremic Encephalopathy- A Neurologist's Point of View
sm171181
Â
Angiotensin receptor blockers
Angiotensin receptor blockers
Mahatma Gandhi Medical College & Hospital
Â
Renal replacement therapy
Renal replacement therapy
Manoj Prabhakar
Â
Hyponatremia ppt .final
Hyponatremia ppt .final
Arun Karmakar
Â
Statin
Statin
Sanjoy Kumar Saha
Â
Antiarrhythmic drugs
Antiarrhythmic drugs
Naser Tadvi
Â
Semaglutide journal club
Semaglutide journal club
Bhargav Kiran
Â
Hypertension 2020 Updated Guidelines
Hypertension 2020 Updated Guidelines
Dr. Aryan (Anish Dhakal)
Â
Antianginal drugs and drugs used in ischaemia - drdhriti
Antianginal drugs and drugs used in ischaemia - drdhriti
http://neigrihms.gov.in/
Â
Stroke
Stroke
Rashna Sharmin
Â
hypernatremia
hypernatremia
Mehakinder Singh
Â
Pharmacological management of migraine
Pharmacological management of migraine
uma advani
Â
Ticagrelor
Ticagrelor
Himanshu Rana
Â
Diabetic dyslipidemia and Saroglitazar
Diabetic dyslipidemia and Saroglitazar
Dr Vivek Baliga
Â
Benzodiazepines toxicity
Benzodiazepines toxicity
Amira Badr
Â
Antipsychotics
Antipsychotics
Naser Tadvi
Â
Hyperkalemia 160108171542
Hyperkalemia 160108171542
Indhu Reddy
Â
Acute kidney injury
Acute kidney injury
aravind ps
Â
What's hot
(20)
Antiplatelet and fibrinolytics
Antiplatelet and fibrinolytics
Â
Ranolazine
Ranolazine
Â
Uremic Encephalopathy- A Neurologist's Point of View
Uremic Encephalopathy- A Neurologist's Point of View
Â
Angiotensin receptor blockers
Angiotensin receptor blockers
Â
Renal replacement therapy
Renal replacement therapy
Â
Hyponatremia ppt .final
Hyponatremia ppt .final
Â
Statin
Statin
Â
Antiarrhythmic drugs
Antiarrhythmic drugs
Â
Semaglutide journal club
Semaglutide journal club
Â
Hypertension 2020 Updated Guidelines
Hypertension 2020 Updated Guidelines
Â
Antianginal drugs and drugs used in ischaemia - drdhriti
Antianginal drugs and drugs used in ischaemia - drdhriti
Â
Stroke
Stroke
Â
hypernatremia
hypernatremia
Â
Pharmacological management of migraine
Pharmacological management of migraine
Â
Ticagrelor
Ticagrelor
Â
Diabetic dyslipidemia and Saroglitazar
Diabetic dyslipidemia and Saroglitazar
Â
Benzodiazepines toxicity
Benzodiazepines toxicity
Â
Antipsychotics
Antipsychotics
Â
Hyperkalemia 160108171542
Hyperkalemia 160108171542
Â
Acute kidney injury
Acute kidney injury
Â
Viewers also liked
Neurotransmitters and its mechanism of action
Neurotransmitters and its mechanism of action
Parthasarathy Ravichandran
Â
Mechanism of drug action
Mechanism of drug action
Deepthi P Ramachandran
Â
FörÀldramöte lövgÀrdesskolan
FörÀldramöte lövgÀrdesskolan
hakan123
Â
performance-people.nl Kasteeldag 2013 - Nieuw Leiderschap
performance-people.nl Kasteeldag 2013 - Nieuw Leiderschap
Robert Schenk
Â
Prediksi soal-un-sma-2012-fisika-ipa
Prediksi soal-un-sma-2012-fisika-ipa
Candra Kurniawan
Â
Rocka
Rocka
gazadi
Â
Fornitura E Finanziamento Di Materiale Per Impianti Fotovoltaici
Fornitura E Finanziamento Di Materiale Per Impianti Fotovoltaici
lucacococcia
Â
Careers
Careers
nghivang
Â
Virtual Fieldwork
Virtual Fieldwork
Rahul Rakshit
Â
Counting Frogs
Counting Frogs
Lake Aik
Â
Đ©ŃŃĐ”ĐČĐžŃ Đ.Đź. ĐĄĐŸĐ·ĐŽĐ°ĐœĐžĐ” ĐžĐœŃĐŸŃĐŒĐ°ŃĐžĐŸĐœĐœĐŸĐłĐŸ ĐżĐŸĐČĐŸĐŽĐ°, ОлО ĐșĐ°Đș ŃĐŸŃŃŃĐŽĐœĐžŃĐ°ŃŃ ŃĐŸ ĐĄĐРбДŃ...
Đ©ŃŃĐ”ĐČĐžŃ Đ.Đź. ĐĄĐŸĐ·ĐŽĐ°ĐœĐžĐ” ĐžĐœŃĐŸŃĐŒĐ°ŃĐžĐŸĐœĐœĐŸĐłĐŸ ĐżĐŸĐČĐŸĐŽĐ°, ОлО ĐșĐ°Đș ŃĐŸŃŃŃĐŽĐœĐžŃĐ°ŃŃ ŃĐŸ ĐĄĐРбДŃ...
prasu1995
Â
Two migration realities
Two migration realities
islaysn
Â
Campeoanto nacional de ruta 2011 cordoba
Campeoanto nacional de ruta 2011 cordoba
ACAM ATLETISMO
Â
PresentaciĂłn efectiva, facebook
PresentaciĂłn efectiva, facebook
plhd
Â
Presentacion de fisica ii
Presentacion de fisica ii
gaonaabelenama
Â
Global Childcare in France
Global Childcare in France
princessfrancisco
Â
Los 80's.
Los 80's.
ENMSI
Â
Lezione2schetchup 111126133835-phpapp01
Lezione2schetchup 111126133835-phpapp01
Giuliana Finco
Â
Iarna Ăźn pÄdure
Iarna Ăźn pÄdure
Fartade Bernadeta
Â
Change One Thing
Change One Thing
Aneesah Bakker
Â
Viewers also liked
(20)
Neurotransmitters and its mechanism of action
Neurotransmitters and its mechanism of action
Â
Mechanism of drug action
Mechanism of drug action
Â
FörÀldramöte lövgÀrdesskolan
FörÀldramöte lövgÀrdesskolan
Â
performance-people.nl Kasteeldag 2013 - Nieuw Leiderschap
performance-people.nl Kasteeldag 2013 - Nieuw Leiderschap
Â
Prediksi soal-un-sma-2012-fisika-ipa
Prediksi soal-un-sma-2012-fisika-ipa
Â
Rocka
Rocka
Â
Fornitura E Finanziamento Di Materiale Per Impianti Fotovoltaici
Fornitura E Finanziamento Di Materiale Per Impianti Fotovoltaici
Â
Careers
Careers
Â
Virtual Fieldwork
Virtual Fieldwork
Â
Counting Frogs
Counting Frogs
Â
Đ©ŃŃĐ”ĐČĐžŃ Đ.Đź. ĐĄĐŸĐ·ĐŽĐ°ĐœĐžĐ” ĐžĐœŃĐŸŃĐŒĐ°ŃĐžĐŸĐœĐœĐŸĐłĐŸ ĐżĐŸĐČĐŸĐŽĐ°, ОлО ĐșĐ°Đș ŃĐŸŃŃŃĐŽĐœĐžŃĐ°ŃŃ ŃĐŸ ĐĄĐРбДŃ...
Đ©ŃŃĐ”ĐČĐžŃ Đ.Đź. ĐĄĐŸĐ·ĐŽĐ°ĐœĐžĐ” ĐžĐœŃĐŸŃĐŒĐ°ŃĐžĐŸĐœĐœĐŸĐłĐŸ ĐżĐŸĐČĐŸĐŽĐ°, ОлО ĐșĐ°Đș ŃĐŸŃŃŃĐŽĐœĐžŃĐ°ŃŃ ŃĐŸ ĐĄĐРбДŃ...
Â
Two migration realities
Two migration realities
Â
Campeoanto nacional de ruta 2011 cordoba
Campeoanto nacional de ruta 2011 cordoba
Â
PresentaciĂłn efectiva, facebook
PresentaciĂłn efectiva, facebook
Â
Presentacion de fisica ii
Presentacion de fisica ii
Â
Global Childcare in France
Global Childcare in France
Â
Los 80's.
Los 80's.
Â
Lezione2schetchup 111126133835-phpapp01
Lezione2schetchup 111126133835-phpapp01
Â
Iarna Ăźn pÄdure
Iarna Ăźn pÄdure
Â
Change One Thing
Change One Thing
Â
Similar to 17. citicoline in ischemic stroke in mexico
CIACI_2015
CIACI_2015
Pawel J. Ciesielczyk, PhD
Â
Estudio NONSEDA.pdf
Estudio NONSEDA.pdf
ssuserb63aff
Â
Nccu journal club 2.5.13
Nccu journal club 2.5.13
Joshua Kornbluth
Â
Apnea
Apnea
MedicinaIngles
Â
Autologous Bone Marrow Cell Therapy for Autism: An Open Label Uncontrolled C...
Autologous Bone Marrow Cell Therapy for Autism: An Open Label Uncontrolled C...
remedypublications2
Â
No association between prepulse inhibition of the startle reïŹex and neuropsyc...
No association between prepulse inhibition of the startle reïŹex and neuropsyc...
Benjamin Cortes
Â
20150300.0 00014
20150300.0 00014
samirsharshar
Â
Treatment of diffuse systemic sclerosis with AIMSPRO
Treatment of diffuse systemic sclerosis with AIMSPRO
Aimspro - Daval International Ltd
Â
is laser treatment is really a good decision for a women????think...Impact of...
is laser treatment is really a good decision for a women????think...Impact of...
ShitalSavaliya1
Â
Translational Neuroscience Approach in psychiatry..pptx
Translational Neuroscience Approach in psychiatry..pptx
krishray616
Â
Burt_MS
Burt_MS
Brandon Benefield
Â
neu%2E2012%2E2782
neu%2E2012%2E2782
Rose McAloon
Â
Article On Memantine-1.pptx
Article On Memantine-1.pptx
Nimish Savaliya
Â
JC HO - Colistin V. Tige - NOWICKI
JC HO - Colistin V. Tige - NOWICKI
Diana Nicole Nowicki, CPhT
Â
Association between moderate intensity physical activity and inflammatory mar...
Association between moderate intensity physical activity and inflammatory mar...
José Hernåndez Soto
Â
Salon a 14 kasim 13.30 14.45 younsuck koh
Salon a 14 kasim 13.30 14.45 younsuck koh
tyfngnc
Â
Estudio clĂnico espalda, revista spine
Estudio clĂnico espalda, revista spine
Dr. Manuel ConcepciĂłn
Â
Autologous Bone Marrow Mononuclear Cell Therapy for Autism: An Open Label Pro...
Autologous Bone Marrow Mononuclear Cell Therapy for Autism: An Open Label Pro...
DrAlokSharma
Â
GIGO Problems With AI.pdf
GIGO Problems With AI.pdf
Nelson Hendler
Â
Trial of Decompressive Craniectomy for Traumatic Intracranial Hypertension
Trial of Decompressive Craniectomy for Traumatic Intracranial Hypertension
MQ_Library
Â
Similar to 17. citicoline in ischemic stroke in mexico
(20)
CIACI_2015
CIACI_2015
Â
Estudio NONSEDA.pdf
Estudio NONSEDA.pdf
Â
Nccu journal club 2.5.13
Nccu journal club 2.5.13
Â
Apnea
Apnea
Â
Autologous Bone Marrow Cell Therapy for Autism: An Open Label Uncontrolled C...
Autologous Bone Marrow Cell Therapy for Autism: An Open Label Uncontrolled C...
Â
No association between prepulse inhibition of the startle reïŹex and neuropsyc...
No association between prepulse inhibition of the startle reïŹex and neuropsyc...
Â
20150300.0 00014
20150300.0 00014
Â
Treatment of diffuse systemic sclerosis with AIMSPRO
Treatment of diffuse systemic sclerosis with AIMSPRO
Â
is laser treatment is really a good decision for a women????think...Impact of...
is laser treatment is really a good decision for a women????think...Impact of...
Â
Translational Neuroscience Approach in psychiatry..pptx
Translational Neuroscience Approach in psychiatry..pptx
Â
Burt_MS
Burt_MS
Â
neu%2E2012%2E2782
neu%2E2012%2E2782
Â
Article On Memantine-1.pptx
Article On Memantine-1.pptx
Â
JC HO - Colistin V. Tige - NOWICKI
JC HO - Colistin V. Tige - NOWICKI
Â
Association between moderate intensity physical activity and inflammatory mar...
Association between moderate intensity physical activity and inflammatory mar...
Â
Salon a 14 kasim 13.30 14.45 younsuck koh
Salon a 14 kasim 13.30 14.45 younsuck koh
Â
Estudio clĂnico espalda, revista spine
Estudio clĂnico espalda, revista spine
Â
Autologous Bone Marrow Mononuclear Cell Therapy for Autism: An Open Label Pro...
Autologous Bone Marrow Mononuclear Cell Therapy for Autism: An Open Label Pro...
Â
GIGO Problems With AI.pdf
GIGO Problems With AI.pdf
Â
Trial of Decompressive Craniectomy for Traumatic Intracranial Hypertension
Trial of Decompressive Craniectomy for Traumatic Intracranial Hypertension
Â
More from Erwin Chiquete, MD, PhD
Mortalidad asociada al diagnĂłstico de sĂndrome de Guillain-BarrĂ© en adultos i...
Mortalidad asociada al diagnĂłstico de sĂndrome de Guillain-BarrĂ© en adultos i...
Erwin Chiquete, MD, PhD
Â
Seroepidemiology of Toxoplasma gondii infection in drivers involved in road t...
Seroepidemiology of Toxoplasma gondii infection in drivers involved in road t...
Erwin Chiquete, MD, PhD
Â
Tiempo de llegada hospitalaria y pronóstico funcional después deun infarto ce...
Tiempo de llegada hospitalaria y pronóstico funcional después deun infarto ce...
Erwin Chiquete, MD, PhD
Â
Comportamiento del barorreflejo en pacientes con sĂncope vasovagal durante el...
Comportamiento del barorreflejo en pacientes con sĂncope vasovagal durante el...
Erwin Chiquete, MD, PhD
Â
DelĂrium en adultos que reciben cuidados paliativos: revisiĂłn de laliteratura...
DelĂrium en adultos que reciben cuidados paliativos: revisiĂłn de laliteratura...
Erwin Chiquete, MD, PhD
Â
Central Adiposity and Mortality after First-Ever Acute Ischemic Stroke
Central Adiposity and Mortality after First-Ever Acute Ischemic Stroke
Erwin Chiquete, MD, PhD
Â
Massive Non-Encephalitic Neurocysticercosis
Massive Non-Encephalitic Neurocysticercosis
Erwin Chiquete, MD, PhD
Â
Cost of care according to disease-modifying therapy in Mexicans with relapsin...
Cost of care according to disease-modifying therapy in Mexicans with relapsin...
Erwin Chiquete, MD, PhD
Â
Blood pressure at hospital admission and outcome after primary intracerebral ...
Blood pressure at hospital admission and outcome after primary intracerebral ...
Erwin Chiquete, MD, PhD
Â
Serum Uric Acid and Outcome after Acute Ischemic Stroke: PREMIER Study
Serum Uric Acid and Outcome after Acute Ischemic Stroke: PREMIER Study
Erwin Chiquete, MD, PhD
Â
Hepatitis C virus infection and type 2 diabetes mellitus in Mexican patients.
Hepatitis C virus infection and type 2 diabetes mellitus in Mexican patients.
Erwin Chiquete, MD, PhD
Â
Atherothrombotic Disease, Traditional Risk Factors, and 4-Year Mortality in a...
Atherothrombotic Disease, Traditional Risk Factors, and 4-Year Mortality in a...
Erwin Chiquete, MD, PhD
Â
Atypical forms of the osmotic demyelination syndrome
Atypical forms of the osmotic demyelination syndrome
Erwin Chiquete, MD, PhD
Â
Spontaneous intracerebral hemorrhage in Mexico: results from a Multicenter Na...
Spontaneous intracerebral hemorrhage in Mexico: results from a Multicenter Na...
Erwin Chiquete, MD, PhD
Â
An Expandable Prosthesis with Dual Cage-and-Plate Function in a Single Device...
An Expandable Prosthesis with Dual Cage-and-Plate Function in a Single Device...
Erwin Chiquete, MD, PhD
Â
Expression profile of BRCA1 and BRCA2 genes in premenopausal Mexican women wi...
Expression profile of BRCA1 and BRCA2 genes in premenopausal Mexican women wi...
Erwin Chiquete, MD, PhD
Â
31. cost of bc care
31. cost of bc care
Erwin Chiquete, MD, PhD
Â
Demencia asociada a intoxicaciĂłn por paradiclorobenceno
Demencia asociada a intoxicaciĂłn por paradiclorobenceno
Erwin Chiquete, MD, PhD
Â
Spontaneous intracerebral hemorrhage in Mexico: results from a Multicenter Na...
Spontaneous intracerebral hemorrhage in Mexico: results from a Multicenter Na...
Erwin Chiquete, MD, PhD
Â
Hemorragia intracerebral espontĂĄnea en MĂ©xico: resultados del Registro Hospit...
Hemorragia intracerebral espontĂĄnea en MĂ©xico: resultados del Registro Hospit...
Erwin Chiquete, MD, PhD
Â
More from Erwin Chiquete, MD, PhD
(20)
Mortalidad asociada al diagnĂłstico de sĂndrome de Guillain-BarrĂ© en adultos i...
Mortalidad asociada al diagnĂłstico de sĂndrome de Guillain-BarrĂ© en adultos i...
Â
Seroepidemiology of Toxoplasma gondii infection in drivers involved in road t...
Seroepidemiology of Toxoplasma gondii infection in drivers involved in road t...
Â
Tiempo de llegada hospitalaria y pronóstico funcional después deun infarto ce...
Tiempo de llegada hospitalaria y pronóstico funcional después deun infarto ce...
Â
Comportamiento del barorreflejo en pacientes con sĂncope vasovagal durante el...
Comportamiento del barorreflejo en pacientes con sĂncope vasovagal durante el...
Â
DelĂrium en adultos que reciben cuidados paliativos: revisiĂłn de laliteratura...
DelĂrium en adultos que reciben cuidados paliativos: revisiĂłn de laliteratura...
Â
Central Adiposity and Mortality after First-Ever Acute Ischemic Stroke
Central Adiposity and Mortality after First-Ever Acute Ischemic Stroke
Â
Massive Non-Encephalitic Neurocysticercosis
Massive Non-Encephalitic Neurocysticercosis
Â
Cost of care according to disease-modifying therapy in Mexicans with relapsin...
Cost of care according to disease-modifying therapy in Mexicans with relapsin...
Â
Blood pressure at hospital admission and outcome after primary intracerebral ...
Blood pressure at hospital admission and outcome after primary intracerebral ...
Â
Serum Uric Acid and Outcome after Acute Ischemic Stroke: PREMIER Study
Serum Uric Acid and Outcome after Acute Ischemic Stroke: PREMIER Study
Â
Hepatitis C virus infection and type 2 diabetes mellitus in Mexican patients.
Hepatitis C virus infection and type 2 diabetes mellitus in Mexican patients.
Â
Atherothrombotic Disease, Traditional Risk Factors, and 4-Year Mortality in a...
Atherothrombotic Disease, Traditional Risk Factors, and 4-Year Mortality in a...
Â
Atypical forms of the osmotic demyelination syndrome
Atypical forms of the osmotic demyelination syndrome
Â
Spontaneous intracerebral hemorrhage in Mexico: results from a Multicenter Na...
Spontaneous intracerebral hemorrhage in Mexico: results from a Multicenter Na...
Â
An Expandable Prosthesis with Dual Cage-and-Plate Function in a Single Device...
An Expandable Prosthesis with Dual Cage-and-Plate Function in a Single Device...
Â
Expression profile of BRCA1 and BRCA2 genes in premenopausal Mexican women wi...
Expression profile of BRCA1 and BRCA2 genes in premenopausal Mexican women wi...
Â
31. cost of bc care
31. cost of bc care
Â
Demencia asociada a intoxicaciĂłn por paradiclorobenceno
Demencia asociada a intoxicaciĂłn por paradiclorobenceno
Â
Spontaneous intracerebral hemorrhage in Mexico: results from a Multicenter Na...
Spontaneous intracerebral hemorrhage in Mexico: results from a Multicenter Na...
Â
Hemorragia intracerebral espontĂĄnea en MĂ©xico: resultados del Registro Hospit...
Hemorragia intracerebral espontĂĄnea en MĂ©xico: resultados del Registro Hospit...
Â
Recently uploaded
Ahmedabad Call Girls Book Now 8980367676 Top Class Ahmedabad Escort Service A...
Ahmedabad Call Girls Book Now 8980367676 Top Class Ahmedabad Escort Service A...
Genuine Call Girls
Â
Circulatory Shock, types and stages, compensatory mechanisms
Circulatory Shock, types and stages, compensatory mechanisms
MedicoseAcademics
Â
Call Girls Kathua Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Kathua Just Call 8250077686 Top Class Call Girl Service Available
Dipal Arora
Â
Chandigarh Call Girls Service â€ïžđ 9809698092 đđ«ŠIndependent Escort Service Cha...
Chandigarh Call Girls Service â€ïžđ 9809698092 đđ«ŠIndependent Escort Service Cha...
Sheetaleventcompany
Â
Call girls Service Phullen / 9332606886 Genuine Call girls with real Photos a...
Call girls Service Phullen / 9332606886 Genuine Call girls with real Photos a...
call girls hydrabad
Â
Call Girls Bangalore - 450+ Call Girl Cash Payment đŻCall Us đ 6378878445 đ đ ...
Call Girls Bangalore - 450+ Call Girl Cash Payment đŻCall Us đ 6378878445 đ đ ...
gragneelam30
Â
Call Girls Mussoorie Just Call 8854095900 Top Class Call Girl Service Available
Call Girls Mussoorie Just Call 8854095900 Top Class Call Girl Service Available
Janvi Singh
Â
Difference Between Skeletal Smooth and Cardiac Muscles
Difference Between Skeletal Smooth and Cardiac Muscles
MedicoseAcademics
Â
Call Girl In Indore đ9235973566đ JustđČ Call Inaaya Indore Call Girls Service ...
Call Girl In Indore đ9235973566đ JustđČ Call Inaaya Indore Call Girls Service ...
Sheetaleventcompany
Â
7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana Gupta
7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana Gupta
Lifecare Centre
Â
Kolkata Call Girls Naktala đŻCall Us đ 8005736733 đ đ Top Class Call Girl Se...
Kolkata Call Girls Naktala đŻCall Us đ 8005736733 đ đ Top Class Call Girl Se...
Namrata Singh
Â
Call Girls Shahdol Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Shahdol Just Call 8250077686 Top Class Call Girl Service Available
Dipal Arora
Â
Cardiac Output, Venous Return, and Their Regulation
Cardiac Output, Venous Return, and Their Regulation
MedicoseAcademics
Â
Premium Call Girls Nagpur {9xx000xx09} â€ïžVVIP POOJA Call Girls in Nagpur Maha...
Premium Call Girls Nagpur {9xx000xx09} â€ïžVVIP POOJA Call Girls in Nagpur Maha...
Sheetaleventcompany
Â
Call Girl in Chennai | Whatsapp No đ 7427069034 đ VIP Escorts Service Availab...
Call Girl in Chennai | Whatsapp No đ 7427069034 đ VIP Escorts Service Availab...
amritaverma53
Â
Dehradun Call Girls Service {8854095900} â€ïžVVIP ROCKY Call Girl in Dehradun U...
Dehradun Call Girls Service {8854095900} â€ïžVVIP ROCKY Call Girl in Dehradun U...
Sheetaleventcompany
Â
đChandigarh Call Girls Service đŻPiya đČđ8868886958đCall Girls In Chandigarh No...
đChandigarh Call Girls Service đŻPiya đČđ8868886958đCall Girls In Chandigarh No...
Sheetaleventcompany
Â
Independent Bangalore Call Girls (Adult Only) đŻCall Us đ 7304373326 đ đ Escor...
Independent Bangalore Call Girls (Adult Only) đŻCall Us đ 7304373326 đ đ Escor...
Sheetaleventcompany
Â
Call Girl In Chandigarh đ9809698092đ JustđČ Call Inaaya Chandigarh Call Girls ...
Call Girl In Chandigarh đ9809698092đ JustđČ Call Inaaya Chandigarh Call Girls ...
Sheetaleventcompany
Â
Chennai âŁïž Call Girl 6378878445 Call Girls in Chennai Escort service book now
Chennai âŁïž Call Girl 6378878445 Call Girls in Chennai Escort service book now
tanudubay92
Â
Recently uploaded
(20)
Ahmedabad Call Girls Book Now 8980367676 Top Class Ahmedabad Escort Service A...
Ahmedabad Call Girls Book Now 8980367676 Top Class Ahmedabad Escort Service A...
Â
Circulatory Shock, types and stages, compensatory mechanisms
Circulatory Shock, types and stages, compensatory mechanisms
Â
Call Girls Kathua Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Kathua Just Call 8250077686 Top Class Call Girl Service Available
Â
Chandigarh Call Girls Service â€ïžđ 9809698092 đđ«ŠIndependent Escort Service Cha...
Chandigarh Call Girls Service â€ïžđ 9809698092 đđ«ŠIndependent Escort Service Cha...
Â
Call girls Service Phullen / 9332606886 Genuine Call girls with real Photos a...
Call girls Service Phullen / 9332606886 Genuine Call girls with real Photos a...
Â
Call Girls Bangalore - 450+ Call Girl Cash Payment đŻCall Us đ 6378878445 đ đ ...
Call Girls Bangalore - 450+ Call Girl Cash Payment đŻCall Us đ 6378878445 đ đ ...
Â
Call Girls Mussoorie Just Call 8854095900 Top Class Call Girl Service Available
Call Girls Mussoorie Just Call 8854095900 Top Class Call Girl Service Available
Â
Difference Between Skeletal Smooth and Cardiac Muscles
Difference Between Skeletal Smooth and Cardiac Muscles
Â
Call Girl In Indore đ9235973566đ JustđČ Call Inaaya Indore Call Girls Service ...
Call Girl In Indore đ9235973566đ JustđČ Call Inaaya Indore Call Girls Service ...
Â
7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana Gupta
7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana Gupta
Â
Kolkata Call Girls Naktala đŻCall Us đ 8005736733 đ đ Top Class Call Girl Se...
Kolkata Call Girls Naktala đŻCall Us đ 8005736733 đ đ Top Class Call Girl Se...
Â
Call Girls Shahdol Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Shahdol Just Call 8250077686 Top Class Call Girl Service Available
Â
Cardiac Output, Venous Return, and Their Regulation
Cardiac Output, Venous Return, and Their Regulation
Â
Premium Call Girls Nagpur {9xx000xx09} â€ïžVVIP POOJA Call Girls in Nagpur Maha...
Premium Call Girls Nagpur {9xx000xx09} â€ïžVVIP POOJA Call Girls in Nagpur Maha...
Â
Call Girl in Chennai | Whatsapp No đ 7427069034 đ VIP Escorts Service Availab...
Call Girl in Chennai | Whatsapp No đ 7427069034 đ VIP Escorts Service Availab...
Â
Dehradun Call Girls Service {8854095900} â€ïžVVIP ROCKY Call Girl in Dehradun U...
Dehradun Call Girls Service {8854095900} â€ïžVVIP ROCKY Call Girl in Dehradun U...
Â
đChandigarh Call Girls Service đŻPiya đČđ8868886958đCall Girls In Chandigarh No...
đChandigarh Call Girls Service đŻPiya đČđ8868886958đCall Girls In Chandigarh No...
Â
Independent Bangalore Call Girls (Adult Only) đŻCall Us đ 7304373326 đ đ Escor...
Independent Bangalore Call Girls (Adult Only) đŻCall Us đ 7304373326 đ đ Escor...
Â
Call Girl In Chandigarh đ9809698092đ JustđČ Call Inaaya Chandigarh Call Girls ...
Call Girl In Chandigarh đ9809698092đ JustđČ Call Inaaya Chandigarh Call Girls ...
Â
Chennai âŁïž Call Girl 6378878445 Call Girls in Chennai Escort service book now
Chennai âŁïž Call Girl 6378878445 Call Girls in Chennai Escort service book now
Â
17. citicoline in ischemic stroke in mexico
1.
Methods and Findings
in Experimental and Clinical Pharmacology 2010, 32(5): ???-??? THOMSON REUTERS Copyright © 2010 Prous Science, S.A.U. or its licensors. All rights reserved. CCC: 0379-0355/2010 DOI: 10.1358/mf.2010.32.5.1465004 ORIGINAL ARTICLE CITICOLINE FOR ACUTE ISCHEMIC STROKE IN MEXICAN HOSPITALS: A RETROSPECTIVE POST- MARKETING ANALYSIS C. LeĂłn-JimĂ©nez1, E. Chiquete2,3, C. CantĂș4, M.J. Miramontes-Saldaña1, M.A. Andrade-Ramos5 and J. Ruiz- Sandoval6 1 Department of Neurology, Hospital Regional Dr. ValentĂn GĂłmez FarĂas, Zapopan, MĂ©xico; 2Department of Internal Medicine, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, MĂ©xico; 3Department of Internal Medicine, Hospital Civil de Guadalajara Fray Antonio Alcalde; Guadalajara, MĂ©xico; 4Department of Neurology, Instituto Nacional de Ciencias MĂ©dicas y NutriciĂłn Salvador ZubirĂĄn, Mexico City, MĂ©xico; 5Department of Neurology and Neurosurgery, Hospital Civil de Guadalajara Fray Antonio Alcalde; Guadalajara, MĂ©xico; 6Department of Neurosciences. Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, MĂ©xico SUMMARY Some neuroprotective agents have shown benefits in animal models, but disappointing results in humans. Citicoline is used in several countries as coadjuvant treatment in acute ischemic stroke (AIS) patients; however, there are no retrospective postmarketing surveillances on the experience of citicoline in Mexico. The aim of this study was to evaluate the correlation between citicoline exposure and functional outcome at discharge and at 30 and 90 days post-stroke, in a retrospective case-control design on systematic descriptive databases from three referral hospitals. Clinical records of 173 consecutively registered patients were analyzed, 86 of whom were treated with citicoline with- in the first 48 h after AIS and the remaining 87 were untreated, randomly selected controls matched for age (± 5 years), gender and NIHSS (± 1 point) at hospital admission. Pretreatment conditions were similar between groups. Compared with controls, exposure to citicoline was associated with a significantly lower 30-day mean and median modified Rankin score (in both, P < 0.05). After paired multivariate analy- ses (controlled for NIHSS, age, gender, hospital arrival in < 24 h, thrombolysis and comorbidities) citicoline was independently associated with a lower 90-day mortality risk (P = 0.047) and with fewer in-hospital complications (mainly infections and sepsis, P = 0.001). In this observational study, citicoline use was correlated with a better functional status and lower rates of short-term mortality, possibly due to fewer in-hospital systemic complications. The putative benefits should be interpreted as clinical associations, since this is not a random- ized, controlled, clinical trial. INTRODUCTION currently used in several countries for the coadjuvant treatment of A number of neuroprotective agents have shown beneficial effects in patients with AIS, with some clinical trials and a meta-analysis acute ischemic stroke (AIS) in preclinical animal models, but disap- showing that the drug increases the probability of full recovery at 3 pointing results when tested in humans (1, 2). Compounds that are months post-stroke (4, 6, 10, 14). However, the use of citicoline is still effective in the laboratory are not always the most efficacious when controversial and there is a need for evaluation of its beneficial used in clinical practice and, therefore, marginal benefits in certain effects in retrospective postmarketing studies in Mexico. Thus, the subgroups are seen when the selected drugs are used in humans (3). aim of our study was to evaluate the effects of citicoline on several outcome events (case fatality rate, functional outcome and in-hospi- Citicoline (CDP-choline, a choline precursor) is an intermediate mol- tal non-neurological systemic complications) during hospitalization ecule in membrane phosphatide biosynthesis with neuroprotec- and at 30 and 90 days postischemic stroke. tive/neurorestorative properties which have been proven in various forms of brain injury, including ischemia (4-14). This compound is SUBJECTS AND METHODS Correspondence: Dr. JosĂ© Luis Ruiz Sandoval, Servicio de NeurologĂa y NeurocirugĂa, Study population Hospital Civil de Guadalajara Fray Antonio Alcalde, Hospital 278, Col. El Retiro, Torre de Especialidades, piso 8, Guadalajara, Jalisco, MĂ©xico. C.P. 44280. E-mail: jorulej-1n This study was a retrospective observational, case-control study @prodigy.net.mx. designed to evaluate the effects of citicoline exposure on short-term 1
2.
CITICOLINE FOR ACUTE
ISCHEMIC STROKE IN MEXICO C. LeĂłn-JimĂ©nez et al. outcomes after acute brain infarction. Patients treated with citicoline primary study outcomes were mortality and functional status at hos- and untreated controls were selected from three systematic descrip- pital discharge and at 30- and 90-day follow-up, as assessed by the tive databases. These registries were originally intended for descrip- modified Rankin Scale (mRS), which evaluates functional neurolog- tive analyses and do not include patients from clinical trials databas- ical status, including death. Other secondary outcomes analyzed in es. All patients included in these registries were treated as usual by order to explore possible implications for the impact of citicoline attending physicians from the three participating centers, with no exposure on primary study outcomes, other than the alleged neuro- bias other than the natural clinical decisions in daily practice. The protective effect of citicoline, were in-hospital non-neurological sys- authors of this paper admitted and treated some of these patients, temic complications (pneumonia, sepsis, inflammatory response but before the present report was devised, analyzed and drafted. syndrome, shock, pressure ulcers, newly diagnosed arrhythmias or From October 2004 to August 2006, consecutive patients with AIS organ failure) and the need for mechanical ventilation or open managed in general wards were prospectively included in the craniectomy. respective stroke registry databases of three tertiary referral centers: Hospital Regional âDr. ValentĂn GĂłmez FarĂasâ, ISSSTE (Zapopan, Statistical analyses Jalisco; Mexico); Hospital Civil de Guadalajara âFray Antonio Alcaldeâ (Guadalajara, Jalisco; Mexico) and Instituto Nacional de Pearsonâs chi-square and Fisher exact tests were used to assess pro- Ciencias MĂ©dicas y NutriciĂłn âSalvador ZubirĂĄnâ (Mexico City). A portions in nominal variables for bivariate and homogeneity (when standardized, structured questionnaire was systematically used to more than two variables). To compare quantitative variables collect data from the caregiver or the patient if possible regarding between two groups, Studentâs t-test and Mann-Whitney U test were demography, relevant antecedents and the current event. Clinical performed in distributions of parametric and nonparametric vari- examinations and brain imaging variables were also registered. A ables, respectively. To find independent predictors for the outcomes total of 87 adult patients with AIS who arrived to hospital in < 48 h of interest, multivariate analyses were constructed by forward step- from the event onset and who received citicoline were identified and wise logistic regression. Adjusted odds ratios with the respective selected from the databases of the three participating centers (1000 95% confidence intervals (CI) are provided. Input variables were cho- mg twice a day for at least 2-4 weeks then 500 mg twice a day for 5- sen if P < 0.2 in bivariate analyses, but relevant risk factors were 7 weeks more, until completion of a total of 9 weeks of treatment). maintained in the models for adjustment. Hospital arrival in < 24 h This time window was chosen due to the high rate of hospital arrival was included in the prediction analyses, as this is the therapeutic within 24-48 h after stroke onset, with an off-time use of neuropro- window recommended by the citicoline manufacturer. The fitness of tection, which was detected in our citicoline cohort (27%). Event the models was evaluated by the Hosmer-Lemeshow goodness-of- onset was considered to be the precise hour in which the neurologi- fit test, which was considered as reliable when P > 0.2. All P values cal deficit was first observed. Ischemic stroke was confirmed by brain are two-sided and considered as significant when P < 0.05. SPSS imaging (head CT and/or MRI) and intracerebral hemorrhage was version 13.0 for windows (SPSS Inc., Chicago, IL, USA) was used in all excluded accordingly. As untreated controls, the clinical records of calculations. 87 patients with AIS who arrived to hospital in < 48 h (23% arrived in 24-48 h from stroke onset) but who did not receive citicoline were RESULTS selected, matched for age (± 5 years), gender (± 2 females) and score We studied 174 patients with AIS who arrived at the hospital in < 48 of the National Institutes of Health Stroke Scale (NIHSS; ± 1 point) at h, 87 of whom received citicoline for the coadjuvant management of hospital admission. The random selection of controls was also per- ischemic stroke and 87 who were matched controls; however, a formed from a coalescent database integrated with the three inde- patient belonging to the citicoline group was lost to follow-up after pendent participating electronic registries. Random selection func- hospital discharge and was excluded from the final analyses (Table tion of the SPSS (SPSS Inc., Chicago, IL) software (version 13.0 for I). No patient was managed in a stroke unit. A total of 23.1% of windows) was used for this process and included matching protocols patients arrived at the hospital in < 3 h from stroke onset (44.1% in < for NIHSS, age and gender. After selection of 87 matched controls, a 6 h, 70% in < 24 h and 30% between 24 and 48 h). Relevant pre- final study database was formed with cases and controls and treatment variables (including hospital arrival, mechanisms of researchers who performed selection and analysis of patients treat- infarction and infarct territory) and risk factors were comparable ed with citicoline and controls were blinded to study outcomes. between the citicoline group and controls (Table I). The use of Clinical evaluators admitted and treated the patients at their discre- thrombolysis was also similar in both groups (Table II). Other in-hos- tion and were not aware of the analysis. The internal Committee of pital events such as the need for mechanical ventilation, open Ethics of our centers approved this study and informed consent was craniectomy and duration of hospitalization were not different obtained from all patients or their closest relatives at inclusion in the between groups. However, compared with no neuroprotection, citi- observational databases. coline use was associated with a lower rate of in-hospital non-neu- rological complications in bivariate analyses (Table II) and a lower Main operational definitions and outcome measures mean (3.09 vs. 3.69 points, respectively; P = 0.03) and median Hypertension and diabetes were defined by the known diagnosis of (3.0 vs. 4.0 points, respectively; P = 0.03) mRS at 30 days post- these conditions (according to standard guidelines) and/or pharma- stroke. These differences on mRS did not remain statistically signifi- cological treatment to lower blood pressure or glucose. Smoking cant at 90 days post-stroke; nevertheless, trends towards better out- was defined as the consumption of an average of 5 cigarettes or comes were consistently observed at 30 and at 90 days post-event more for at least 2 days per week during 12 months or longer. The (Table II). 2 THOMSON REUTERS â Methods and Findings in Experimental and Clinical Pharmacology 2010, 32(5)
3.
C. León-Jiménez et
al. CITICOLINE FOR ACUTE ISCHEMIC STROKE IN MEXICO Table I. Clinical characteristics of the citicoline group and matched controls. All patients Citicoline Controls Variables (N = 173) (N = 86) (N = 87) P value* Age, mean (range), y 69.1 (36-95) 68.6 (36-94) 69.6 (36-95) 0.67 Female gender, n (%) 90 (52) 44 (51.2) 46 (52.9) 0.82 Main risk factors Hypertension, n (%) 128 (74.0) 61 (70.9) 67 (77.0) 0.36 Current smoking habit, n (%) 71 (41.0) 32 (37.2) 39 (44.8) 0.31 Diabetes, n (%) 56 (32.4) 27 (31.4) 29 (33.3) 0.78 Previous brain infarction, n (%) 32 (18.5) 14 (16.3) 18 (20.7) 0.45 Ischemic heart disease, n (%) 27 (15.6) 13 (15.1) 14 (16.1) 0.86 Transient ischemic attack, n (%) 17 (9.8) 8 (9.3) 9 (10.3) 0.82 Arrival to hospital in < 24 h, n (%) 130 (75.1) 63 (73.3) 67 (77.0) 0.57 NIHSS at hospital arrival, median (range) 14.32 (1-38) 14.30 (1-38) 14.33 (1-38) 0.98 Neurovascular syndrome (TOAST classification) Large-artery atherosclerosis, n (%) 29 (16.8) 15 (17.4) 14 (16.1) 0.81 Cardioembolic, n (%) 41 (23.7) 20 (23.3) 21 (24.1) 0.89 Lacune, n (%) 39 (22.5) 22 (25.6) 17 (19.5) 0.34 Other specified causes, n (%) 6 (3.5) 2 (2.3) 4 (4.6) 0.41 Undetermined mechanism, n (%) 68 (39.3) 31 (36.0) 37 (42.5) 0.38 MCA territory, n (%) 130 (75.1) 65 (75.6) 65 (74.7) 0.89 Posterior circulation brain infarction, n (%) 29 (16.8) 13 (15.1) 16 (18.4) 0.56 MCA, middle cerebral artery; NIHSS, National Institutes of Health Stroke Scale; TOAST, Trial of ORG-10172 in Acute Atroke Treatment. *P value for differences between patients treated with citicoline and controls; Pearson chi-square, Fisher exact test or Studentâs t-test, as corresponded. Table I. Main outcome measures in the citicoline group and matched controls. All patients Citicoline Controls Variables (N = 173) (N = 86) (N = 87) P value* Use of thrombolysis, n (%) 2 (1.1) 1 (1.2) 1 (1.1) 0.89 Duration of hospitalization, median (range) 10.06 (1-92) 10.81 (1-92) 9.33 (1-55) 0.37 Mechanical ventilation, n (%) 21 (12.3) 10 (11.9) 11 (12.6) 0.88 Open craniectomy, n (%) 5 (2.9) 2 (2.4) 3 (3.4) 0.68 In-hospital systemic complications, n (%) 66 (38.6) 24 (28.6) 42 (48.3) 0.008 Urinary tract infections, n (%) 28 (16.4) 14 (16.7) 14 (16.1) 0.92 Pressure ulcers, n (%) 7 (4.1) 3 (3.6) 4 (4.6) 0.99 Acute renal failure, n (%) 9 (5.3) 3 (3.6) 6 (6.9) 0.50 Pneumonia, n (%) 40 (23.4) 16 (19.0) 24 (27.6) 0.19 Acute heart failure, n (%) 12 (7) 3 (3.6) 9 (10.3) 0.13 Arrhythmias, n (%) 22 (12.9) 7 (8.3) 15 (17.2) 0.08 Other systemic complications, n (%)â 50 (29.2) 18 (21.4) 32 (36.8) 0.03 30-Day post-stroke outcome mRS = 0, n (%) 10 (5.8) 8 (9.3) 2 (2.3) 0.06 mRS = 0-1, n (%) 34 (19.7) 21 (24.4) 13 (14.9) 0.12 mRS = 0-2, n (%) 55 (31.8) 31 (36.0) 24 (27.6) 0.23 Death, n (%) 31 (17.9) 11 (12.8) 20 (23) 0.08 90-Day post-stroke outcome mRS = 0, n (%) 19 (11.0) 12 (14.0) 7 (8.0) 0.21 mRS = 0-1, n (%) 44 (25.4) 26 (30.2) 18 (20.7) 0.15 mRS = 0-2, n (%) 65 (37.6) 37 (43.0) 28 (32.2) 0.14 Death, n (%) 36 (20.8) 13 (15.2) 23 (26.4) 0.06 mRS, modified Rankin score. *P value for differences between the citicoline group and controls; Pearson chi-square, Fisher exact test or Studentâs t-test (for means), as corresponded. â Deep vein thrombosis, pulmonary embolism, sepsis, systemic inflammatory response syndrome, multiorgan failure and shock. THOMSON REUTERS â Methods and Findings in Experimental and Clinical Pharmacology 2010, 32(5) 3
4.
CITICOLINE FOR ACUTE
ISCHEMIC STROKE IN MEXICO C. LeĂłn-JimĂ©nez et al. Multivariate analyses were constructed to find predictors of the out- in our study compared to original clinical trials, where the therapeu- comes of interest and to evaluate the independent effect of citicoline tic window was < 24 h and only supratentorial and mainly lobar treatment on these clinical end points (Fig. 1). Adjusting for age, brain infarction cases were assessed. This could also account for the gender, NIHSS at hospital admittance, hospital arrival in < 24 h and differences between our study and previous reports. Nonetheless, relevant risk factors (such as hypertension, diabetes, smoking and the use of citicoline was associated with a modest reduction in mor- other factors), citicoline treatment was independently associated tality during short-term follow-up. with a lower 30- and 90-day mortality risk, as well as with a lower In Mexico where intravenous thrombolysis is used in only 0.6% of rate of systemic non-neurological complications acquired during patients with AIS (24), citicoline could be a cost-effective coadjuvant hospitalization (see Fig. 1A). However, after excluding patients who therapy given its benefits on short-term outcome. Longer periods of received thrombolysis (n = 7, remaining 166 patients), citicoline observation are necessary in order to better clarify the benefits in treatment was only marginally associated with a lower 90-day mor- preventing functional disabilities. As most expenses are incurred tality risk, but was highly significant with respect to in-hospital non- during the first months after AIS and given that this burden is main- neurological complications (see Fig. 1B). ly related to direct hospitalization costs (22, 25), a fairly safe and low-cost therapeutic strategy with a low probability of in-hospital DISCUSSION complications and severe sequelae or death at short-term would be AIS is the second leading cause of death and the first cause of cost-effective. Moreover, the fact that citicoline can also have some acquired adult disability in industrialized countries (15). Rapid inter- benefit in intracerebral hemorrhage (12) and given its wide thera- vention after the onset of a stroke can limit the neurological damage peutic window, treatment with this drug can be initiated even before a brain imaging study is obtained. Whether on-the-field administra- and improve functional recovery (16). In many countries the only tion of citicoline (i.e., before hospital arrival) results in added bene- medical treatment approved for AIS is thrombolysis with alteplase, fits to standard or recommended protocol is an issue that should be and it can be initiated within the first 4.5 h after the event onset (17, studied in the near future. 18). This strategy should be the standard of care in every country. But its brief therapeutic window, the latent risk of bleeding, the absolute In the present study, the use of citicoline was associated with a lower need for neuroimaging before treatment can be initiated and the risk of systemic non-neurological complications during hospitaliza- required training with drug use have limited its use to less than 5% tion. Some previous reports suggest the rationale of this beneficial of stroke patients (19). Developing nations still have pending issues effect, mainly related to outcome after systemic infections and organ in acute care, as well as in primary and secondary stroke prevention. failure (26-29). Given the membrane-stabilizing, free-radical scav- It is necessary that the best current standard-of-care treatments be enging and surfactant-precursor properties (11, 29), citicoline could adapted to these scenarios, and that more cost-effective and widely have a pleiotropic effect in severely ill patients. In animal models citi- applicable therapeutic strategies are available in developing nations coline has been shown to stabilize catecholamine release after brain (19). Neuroprotective and neurorestorative strategies appear to be injury (30, 31). Attenuation of sympathetic activation by citicoline feasible, but neuroprotection in patients with acute stroke has could be a predictor of a better outcome that occurs with beta- demonstrated limited efficacy thus far (20, 21), and cost-effective blockers, for example (32, 33). However, it is necessary to explore analysis of these strategies are difficult to perform in countries in these hypotheses in clinical studies designed ad hoc, since the pres- which wide disparities are observed between the public and private ent study involved multiple testing, which suggests that a high rate sectors (22). of false positives could be observed by chance only, especially when determining secondary outcomes. Unless otherwise stated with future results of the ICTUS study (23), citicoline as a coadjuvant therapy in AIS appears to show benefit in Our study has several limitations, and therefore, the results should be mid-term functional outcomes (10, 11, 14). In the present study, the interpreted with caution. Given that some technical violations to the use of citicoline was associated with a lower risk of short-term mor- manufacturerâs recommendations were observed with the use of citi- tality and trends that consistently showed better functional status coline in our population (mainly with respect to stroke severity, thera- when compared to no neuroprotection. With a higher probability of peutic window and brain infarct territory) (seeTable I), it was difficult surviving and a better short-term functional status, our study sug- to select a homogeneous and large sample size sufficiently powered gests that citicoline could be efficacious and cost-effective when to detect minor differences in pretreatment variables and outcomes. added to the standard management of ischemic stroke patients in This behavior in drug use is a common phenomenon observed after general wards. Whether this drug adds some benefit to the patient market launching and it is not rare that some off-label use of drugs managed completely in a stroke unit or with thrombolytics is a topic pave the way for new uses and indications. That the multivariate that could not be explored in our study. However, none of the previ- analyses changed after excluding the few patients who received ous studies (either experimental or observational) on the use of citi- thrombolysis could reflect the inherent problems of a small sample coline in acute AIS reported a reduction in mortality (4-10, 12). This size. Nevertheless, as was shown in a previous large descriptive report (14), it seems reasonable to administer citicoline, since its use in nor- could be due to a significant correlation between citicoline use and a mal clinical settings (outside clinical trials) has been associated with low rate of systemic non-neurological complications during hospital a better outcome compared with no neuroprotection. stay, since the reduction of systemic complications was greater than that for mortality. Alternatively, it is possible that patients with a bet- In conclusion, this postmarketing analysis shows that treatment with ter chance of survival were intentionally given citicoline as a treat- citicoline is associated with several clinical benefits that should be ment intervention. Citicoline was used in a slightly different scenario clarified in further experimental studies. This is a retrospective, 4 THOMSON REUTERS â Methods and Findings in Experimental and Clinical Pharmacology 2010, 32(5)
5.
C. León-Jiménez et
al. CITICOLINE FOR ACUTE ISCHEMIC STROKE IN MEXICO Figure 1. Forest plots showing the odds ratios (95% CI) obtained in 10 multivariate analyses on the main outcome measures: 5 logistic regression models for model 1, and the other 5 for model 2. (A) Model 1, including patients who received thrombolysis (total, n = 173). (B) Model 2, excluding patients who received thrombolysis (total, n = 166). Variables analyzed in each model: age, gender, NIHSS at hospital admission, hospital arrival in < 24 h, citicoline use, diabetes, hypertension, smoking and previous acute cerebrovascular disease. Only variables significantly associated with the outcome measures are shown in the table. In all models Hosmer-Lemeshow test for goodness of fit had P > 0.20 (regarded as reliable). THOMSON REUTERS â Methods and Findings in Experimental and Clinical Pharmacology 2010, 32(5) 5
6.
CITICOLINE FOR ACUTE
ISCHEMIC STROKE IN MEXICO C. LeĂłn-JimĂ©nez et al. observational case-control analysis not sufficiently powered to 13. Fioravanti, M., Buckley, A.E. Citicoline (Cognizin) in the treatment of cog- detect minor differences between groups. It implies a methodologi- nitive impairment. Clin Interv Aging 2006, 1(3): 247-51. cal limitation when trying to explain benefits associated with drug 14. Cho, H.J., Kim, Y.J. Efficacy and safety of oral citicoline in acute ischemic intervention. The finding that citicoline is associated with a lower risk stroke: Drug surveillance study in 4,191 cases. Methods Find Exp Clin of systemic non-neurological medical complications is an issue that Pharmacol 2009, 31(3): 171-6. should be investigated in the future. 15. Mackay, J., Mensah, G.A. (Editors): The Atlas of Heart Disease and Stroke. World Health Organization. Myriad Editions Ltd., Brighton, 2004. ACKNOWLEDGMENTS 16. Hacke, W., Donnan, G., Fiesch, C. et al. Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA This study was partially supported by Ferrer Grupo SA (Barcelona, stroke trials. Lancet 2004, 363(9411): 768-74. Spain). The company did not participate, either directly or indirectly, 17. Hacke, W., Kaste, M., Bluhmki, E. et al. Thrombolysis with alteplase 3 to 4.5 in the study design, random selection of controls, patient selection, hours after acute ischemic stroke. N Engl J Med 2008, 359(13): 1317-29. data capture, data analysis, manuscript draft or the decision to sub- 18. Wahlgreen, N., Ahmed, N., DĂĄvalos, A. et al. Thrombolysis with alteplase mit for publication. 3-4.5 h after acute ischaemic stroke (SITS-ISTR): An observational study. Lancet 2008, 372(9646): 1303-9. DISCLOSURES 19. Durai Pandian, J., Padma, V., Vijaya, P., Sylaja, P.N., Murthy, J.M. Stroke and thrombolysis in developing countries. Int J Stroke 2007, 2: 17-26. The authors state no conflicts of interest. 20. Lees, K.R., Asplund, K., Carolei, A. et al. Glycine antagonist (gavestinel) in neuroprotection (GAIN international) in patients with acute stroke. A ran- REFERENCES domised controlled trial. GAIN International Investigators. Lancet 2000, 1. Gladstone, D.J., Black, S.E., Hakim, A.M.; Heart and Stroke Foundation of 355(9219): 1949-54. Ontario Centre of Excellence in Stroke Recovery. Toward wisdom from 21. Muir, K.W., Lees, K.R., Ford, I., Davis, S. Magnesium for acute stroke (intra- failure: Lessons from neuroprotective stroke trials and new therapeutic venous magnesium efficacy in stroke trial). A randomised controlled trial. directions. Stroke 2002, 33(8): 2123-36. Lancet 2004, 363(9407): 439-45. 2. Diener, H.C., Lees, K.R., Lyden, P. et al. NXY-059 for the treatment of 22. MartĂnez, H.R., Rangel-Guerra, R.A., Marfil-Rivera, A., Muñiz, C.E., acute stroke: Pooled analysis of the SAINT I and II trials. Stroke 2008, SagĂĄstegui, A. Cost of stroke in Mexico. J Stroke Cerebrovasc Dis 1995, 4: 39(6): 1751-8. 244-47. 3. OâCollins, V.E., MacLeod, M.R., Donnan, G.A., Horky, L.L., Van Der Worp, 23. Stroke trials registry. The Internet Stroke Center. Accessed October 12, B.H., Howells, D.W. 1,026 experimental treatments in acute stroke. Ann 2008. (http://www.strokecenter.org/trials). Neurol 2006, 59(3): 467-77. 24. Ruiz-Sandoval, J.L., Murillo-Bonilla, L.M., Chiquete, E. et al. First Mexican 4. Tazaki, Y., Sakai, F., Otomo, E et al. Treatment of acute cerebral infarction multicenter register on ischemic stroke (the PREMIER Study): with a choline precursor in a multicenter double-blind controlled study. Demographics, risk factors and outcome. Stroke 2009, 40(4): S85. Stroke 1988, 19(2): 211-6. 25. Epstein, D., Mason, A., Manca, A. The hospital costs of care for stroke in 5. Clark, W.M., Warach, S.J., Pettigrew, L.C., Gammans, R.E., Sabounjian, nine European countries. Health Econ 2008, 17(S1): S21-31. L.A. A randomized dose-response trial of citicoline in acute ischemic stroke 26. Banna, P., Marcello, M.F., Murabito, R. et al. Ultrastructural changes of the patients. Citicholine Stroke Study Group. Neurology 1997, 49(3): 671-8. pulmonary parenchyma after experimentally induced endotoxic shock in 6. Clark W.M., Williams B.J., Selzer K.A., Zweifler R.M., Sabounjian L.A., dogs with and without drug protection. Respiration 1985, 47(3): 177-84. Gammans R.E. A randomized efficacy trial of citicoline in patients with 27. Dulchavsky, S.A., Ksenzenko, S.M., Saba, A.A., Diebel, L.N. acute ischemic stroke. Stroke 1999, 30(12): 2592-7. Triiodothyronine (T3) supplementation maintains surfactant biochemical 7. Warach, S., Pettigrew, L.C., Dashe, J.F. et al. Effect of citicoline on ischemic integrity during sepsis. J Trauma 1995, 39(1): 53-7. lesions as measured by diffusion-weighted magnetic resonance imaging. 28. Yilmaz, Z., Ilcol, Y.O., Torun, S., Ulus, I.H. Intravenous administration of Citicoline 010 Investigators. Ann Neurol 2000, 48(5): 713-22. choline or CDP-choline improves platelet count and platelet closure times 8. Baskaya, M.K., Dogan, A., Rao, A.M., Dempsey, R.J. Neuroprotective in endotoxin-treated dogs. Shock 2006, 25(1): 73-9. effects of citicoline on brain edema and blood-brain barrier breakdown 29. Jambou, R., El-Assaad, F., Combes, V., Grau, G.E. Citicoline (CDP-choline): after traumatic brain injury. J Neurosurg 2000, 92: 448-52. What role in the treatment of complications of infectious diseases. Int J 9. Clark, W.M., Wechsler, L.R., Sabounjian, L.A., Schwiderski, U.E.; Biochem Cell Biol 2009, 41(7): 1467-70. Citicoline Stroke Study Group. A phase III randomized efficacy trial of 30. Boismare, F.R., Leponcin, M., Lefrancois, J.P., Hacpille, L., Marchand, J.C. 2000 mg citicoline in acute ischemic stroke patients. Neurology 2001, [Effect of cytidine diphosphocholine on hemodynamic, functional and bio- 57(9): 1595-602. chemical consequences of cranio-cervical trauma in rats]. ThĂ©rapie 1977, 10. DĂĄvalos, A., Castillo, J., Alvarez-SabĂn, J. et al. Oral citicoline in acute 32: 345-54. ischemic stroke: An individual patient data pooling analysis of clinical tri- 31. Hurtado, O., Moro, M.A., CĂĄrdenas, A., et al. Neuroprotection afforded by als. Stroke 2002, 33(12): 2850-7. prior citicoline administration in experimental brain ischemia: Effects on 11. Secades, J.J., Lorenzo, J.L. Citicoline: Pharmacological and clinical review, glutamate transport. Neurobiol Dis 2005, 18(2): 336-50. 2006 update. Methods Find Exp Clin Pharmacol 2006, 28(Suppl. B): 1- 32. Dziedzic, T., Slowik, A., Pera, J., Szczudlik, A. Beta-blockers reduce the risk 56. of early death in ischemic stroke. J Neurol Sci 2007; 252(1): 53-56. 12. Secades, J.J., Alvarez-SabĂn, J., Rubio, F. et al. Citicoline in intracerebral 33. Sander, D., Winbeck, K., Klingelhöfer, J., Etgen, T., Conrad, B. Prognostic haemorrhage: A double-blind, randomized, placebo-controlled, multi-cen- relevance of pathological sympathetic activation after acute thromboem- tre pilot study. Cerebrovasc Dis 2006, 21(5-6): 380-5. bolic stroke. Neurology 2001, 57(5): 833-8. 6 THOMSON REUTERS â Methods and Findings in Experimental and Clinical Pharmacology 2010, 32(5)
Download now